Lastly, patients with multiple myeloma have been able to benefit from CAR-T therapies since March 2021, as the FDA granted approval of CAR-T targeting B Cell Maturation Antigen (BCMA) after resistance or relapse to four prior lines. Here, TNFRSF17 is linked to plasma cell myeloma.